Who Decides What at MEDVi: Costs, Approval, and What Can Change This section explains how responsibility is divided between the MEDVi platform and licensed clinicians, and which parts of the program can change by case
Think simple, bland, protein-forward meals for the first seven days
It has not received FDA approval for weight loss, obesity, or type 2 diabetes
Supervised GLP-1 Care at GoalBMI Wellness The discontinuation data makes a clear case for physician supervision patients managing symptoms alone stop treatment at higher rates than those with clinical support
Semaglutide is a proven, FDA-approved GLP-1 agonist for weight loss (1520% body weight reduction in clinical trials) Tirzepatide is a dual GIP/GLP-1 agonist showing up to 22% weight loss in trials often more potent than Semaglutide for some patients Retatrutide is an experimental triple agonist with promising early results, but is NOT FDA-approved and not yet available at Better Med Spa All three require medical supervision, lifestyle changes, and ongoing monitoring for safe, sustainable results Better Med Spa in Lincoln Park currently offers Semaglutide and Tirzepatide with physician-directed protocols, slow titration, and holistic wellness integration Quick Comparison: Semaglutide vs
